Compounds and combinations thereof for treating neurological and psychiatric conditions
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
1. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience depersonalization or derealization disorder, and wherein the combination of the dextromethorphan and the bupropion are administered in a dosage form that further comprises an L-cysteine.
2. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience depersonalization or derealization disorder, and wherein the human patient is monitored for any indication of clinical worsening.
3. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience depersonalization or derealization disorder, and wherein the human patient is monitored for any emergence of suicidal thoughts or behaviors.
4. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience sedation, and wherein the combination of the dextromethorphan and the bupropion are administered in a dosage form that further comprises an L-cysteine.
5. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience sedation, and wherein the human patient is monitored for any indication of clinical worsening.
6. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience sedation, and wherein the human patient is monitored for any emergence of suicidal thoughts or behaviors.
7. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience a clinically significant prolongation of the QT interval, and wherein the combination of the dextromethorphan and the bupropion are administered in a dosage form that further comprises an L-cysteine.
8. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience a clinically significant prolongation of the QT interval, and wherein the human patient is monitored for any indication of clinical worsening.
9. A method of treating depression in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in depression symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience a clinically significant prolongation of the QT interval, and wherein the human patient is monitored for any emergence of suicidal thoughts or behaviors.